The Biomanufacturing World Summit is a premier gathering of industry leaders, biomanufacturing executives, and experts dedicated to exploring innovative strategies, emerging trends, and best practices in the dynamic world of biomanufacturing.
BMWS gathers Senior Manufacturing Executives, Technical Operations Quality Executives, and Biomanufacturing Executives to share insights, foster innovation, and build invaluable connections. Dive into a thoughtfully curated environment that brings together thought leaders, allowing you to explore new ideas and engage in meaningful discussions. Join the conversation at BMWS and be part of a community dedicated to pushing the limits of biomanufacturing success.
Year after year, we bring to the stage today's thought leaders and innovators
Sanat Chattopadhyay is responsible for Merck’s worldwide manufacturing and supply operations supporting annual global sales revenues exceeding $40 billion. Merck is known as MSD outside of the U.S. and Canada.
Sanat oversees a network of 50 pharmaceuticals, vaccines, biologics/therapeutic proteins and animal health manufacturing, commercialization and distribution sites with approximately 20,000 staff in over 20 countries around the world producing annually 17.5 billion tablets, 700M injectables, 1 billion packs, and 90 billion animal health vaccines doses in 22,000 product finishes. He also serves on Merck’s Executive Committee.
In his current role, he has successfully launched a new strategy for the manufacturing and supply organization, restructured the organization into four independent, interconnected business units, and further integrated supply planning and operations across the company.
He has a 30-year track record of success in commercialization, manufacturing and supply chain excellence in therapeutic proteins, vaccines and pharmaceuticals for Hoechst, Aventis, Wyeth and Merck.
Before joining Merck in November 2009, Sanat worked for Wyeth Pharmaceuticals as Senior Vice President, New Products & Process Development. A graduate Chemical Engineer and a post-graduate Industrial Engineer from India, Sanat started his career with Hoechst Pharmaceuticals in 1983 and worked in many senior leadership assignments in 5 countries across 3 continents, rising to the level of Senior Vice President, Product Development & Supply at Aventis where he led global supply chain, including new product commercialization, technology and engineering.
Outside Merck, Sanat serves on the Board of Directors of Hilleman Laboratories, an equal joint-venture partnership formed between Merck and the Wellcome Trust, a global charitable foundation dedicated to human and animal health. He is also a member of the Advisory Board of the USA-India Chamber of Commerce.
Sanat Chattopadhyay
EVP, President Merck Manufacturing Division
Merck
Mike and the Pfizer Global Supply (PGS) team work to ensure uninterrupted supply for Pfizer’s entire product portfolio, which includes hundreds of medicines and vaccines – more than 38 billion doses each year. The PGS network includes approximately 30,000 colleagues and contractors and 39 Pfizer global manufacturing sites.
Mike McDermott
EVP, Chief Global Supply Officer
Pfizer
Jerry Murry, is Senior Vice President of Process Development at Amgen. Jerry started his career at Amgen in 2006 as Executive Director, Process Development within the Translational Sciences organization in R&D, and was promoted to Vice President, Process Development in 2010. In 2012, Jerry joined the Amgen Full Potential Transformation team as lead of the initiative “Transforming Process Development at Amgen”(AFP3).
In 2014, as part of the integration and reorganization of a new single, global process development team, Jerry was named the head of CMC Lifecycle management with responsibility for Operations Commercialization activities including regulatory filings and launches.
In 2016, Jerry became head of Drug Product Technologies with responsibility for all formulation and product and process development.
In 2018, Jerry was promoted to Senior Vice President Process Development at Amgen with responsibilities for all global Process Development activities.
Prior to joining Amgen, Jerry spent 8 years at Pfizer Central Research and 6 years at Merck Research Laboratories in Process Development.
Jerry earned BA/BS in Biology and Chemistry at Texas Lutheran University, a PhD in Chemistry from University of Utah and was an NIGMS NIH Fellow at Harvard University.
Jerry Murry
SVP Process Development
Amgen
Tongtong joined Genentech in 2018 as the head of Pharmaceutical Technical Development for US Biologics, and was named global head of Pharma Technical Development in April 2021. Prior to her role at Genentech, Tongtong held several scientific, managerial and strategic roles at Eli Lilly, with increasing responsibilities in the Bioproduct Research and Development organisation. Tongtong also worked at Corixa Corporation, a biotech company, where she gained valuable experiences both as a discovery scientist and as a CMC leader in support of therapeutic antibody and cancer vaccine platforms.
Tongtong received her B. Sc. in Molecular Biology from University of Science and Technology of China, a doctorate in Biology from Syracuse University, and completed her postdoctoral training in cell biology and yeast genetics at Cornell University.
Tongtong Wang
SVP, Global Head Technical Development
Roche
Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women’s Hospital in Boston. He has worked in academic settings teaching and caring for patients and in industry on drug development. He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in January 2016.
Peter Marks
Director, Center for Biologics Evaluation and Research (CBRE)
FDA
Tina Self is a dynamic leader with over 20 years of experience in the biotech and pharmaceutical industries, specializing in quality and manufacturing. Currently, she serves as the Senior Vice President of Global Biologics Manufacturing and Berkeley Site Head at Bayer. Tina has been with Bayer for over eight years, where she has held several key leadership roles, including Vice President of Manufacturing Operations and Vice President of Quality. She is recognized for her strategic oversight of manufacturing processes, commitment to quality assurance, and her ability to drive continuous improvement. Tina holds an MS in Biotechnology from The Johns Hopkins University and an MBA in International Business from Florida Atlantic University.
Tina Self
SVP, Global Biologics Manufacturing and Berkeley Site Head
Bayer
Pascal leads Russell Reynolds’ operations in New York and Canada. He works closely with our healthcare clients around the globe, advising them on their talent strategy, including leadership assessment, succession planning, and the recruitment of directors, CEOs, and other senior executives.
Within the healthcare industry, Pascal specializes in biotech and pharma technical operations, including process development, manufacturing, quality, engineering, and supply chain leadership.
Pascal received his Bachelor of Engineering Physics degree from the Royal Military College of Canada and trained as an aerospace engineer with the Royal Canadian Air Force. He also earned master’s and doctorate degrees in business administration from Athabasca University in Canada, where he focused his research and dissertation on CEO succession. Pascal speaks fluent French and English.
Pascal Bécotte
Managing Director
Russell Reynolds
Laurent Rossi serves as a senior advisor to the Renault Group and is the former Chief Executive Officer of Alpine Racing SAS and chairman of Alpine Racing Ltd. Rossi previously served as Renault’s Chief Strategy Officer and was appointed CEO in 2021 with the Alpine name joining the Formula 1 grid ahead of the 2021 FIA Formula 1 World Championship season.
He began his career at Renault in Paris before earning his MBA from Harvard Business School and joining Boston Consulting Group, where he worked in the New York office. As an automotive expert, he was a consultant on several strategic and operational assignments, working with major global automakers and parts suppliers. He covered the entire value chain from design to sales, including powertrain strategy, manufacturing, and supply chain.
In 2012, he moved to Google, taking charge of developing commercial relations with major automotive industry companies, initially based in Paris for the Europe region, then in New York for the Americas region. Rossi eventually served as the head of Google’s Global Auto Practice, before returning to Renault in February 2018. After a short period heading the Organization Department, he was appointed as VP of Corporate Strategy and Business Development.
Rossi holds a Master of Science in Fluid Mechanics from ENSEEIHT (Toulouse) and a Master of Science in Mechanical Engineering / Automotive Engines & Petroleum Products from IFP School.
Laurent Rossi
Former CEO
Alpine (F1) and Google Executive
Dr. Alison Moore is a CMC Executive who most recently served as the Chief Technical Officer at Allogene Therapeutics. Prior to this role, Moore served as Senior Vice President, Process Development, in Amgen Operations. Moore was previously vice president, Process and Product Engineering (P&PE), where she was responsible for Process Development, Clinical Operations and Global Operations Planning. Moore served as vice president, Corporate Manufacturing, overseeing Supply Chain, Contract Manufacturing, Global Distribution, Manufacturing Technologies, and Operations Risk Management. Before taking on this position, she was vice president, Site Operations at Amgen’s Fremont, California, manufacturing facility (AFR).
Before heading up the AFR facility, Moore was a director in Chemistry, Manufacturing and Controls Regulatory Affairs at Genentech. Prior to her time at Genentech, Moore had previously spent nine years at Amgen in various positions of increasing responsibility within the Process Development organization.
Moore holds a Ph.D. in Cell Biology from Manchester University, England, and a bachelor’s in Pharmacology with Honors from Manchester University, England. Following her doctoral degree work at Manchester University, she was a Postdoctoral Research Fellow at the Medical University of Lübeck, Germany, and at Genentech.
Alison Moore
CMC Executive, Board Member
Jack Garvey, founder of Compliance Architects®, is a seasoned FDA compliance expert with nearly 30 years of leadership experience at industry giants like Johnson & Johnson and C.R. Bard. Combining his chemical engineering and law background, Jack provides practical solutions to minimize FDA enforcement risk. His firm specializes in hands-on GMP consulting, quality, and compliance. Jack is celebrated for his straightforward FDA compliance approach, showcased through blogs, webinars, and public speaking. He’s committed to reducing enforcement risk through diligence, investment, and innovation.
Jack Garvey
CEO/ Managing Partner
Compliance Architects LLC
Tim Moore is Executive Vice President, Chief Technical Officer for Allogene, overseeing product sciences, supply chain, manufacturing, quality and technical operations. Tim has more than three decades of leadership experience in biopharmaceutical manufacturing and operations and was responsible for the global development of two of the most successful autologous CAR T manufacturing processes in the industry. Prior to roles as Chief Operating Officer of Instil Bio, and President and Chief Operating Officer of PACT Pharma, Tim was Executive Vice President, Technical Operations at Kite Pharma (now a Gilead company) from 2016 to 2019, where he was responsible for the process development, manufacturing, quality and supply chain for Yescarta®, the first FDA approved CAR T therapy for the treatment of non-Hodgkin lymphoma. He and his team also developed the manufacturing process for Kite’s second FDA approved autologous CAR T therapy, Tecartus®. Tim previously served as Senior Vice President, Head of Global Technical Operations – Biologics of Genentech, Inc. and as a member of the Genentech Executive Committee where he oversaw global leadership for more than 7,500 professionals across 10 internal sites and over 37 contract manufacturing organizations, as well as global manufacturing and end-to-end quality supply performance of more than 20 biological product families. Tim serves as a Board member for Cerus and BioLife Solutions. He received a B.S. in Chemical Engineering from Tulsa University and a M.S. in Engineering Management from Northwestern University.
Tim Moore
EVP, Chief Technical Officer
Allogene
Dr. Pat Yang is one of the most accomplished biotech manufacturing executives and technical operations leaders in the industry.
From 2017 to 2019, Pat was executive vice president at Juno Therapeutics, a leading CAR-T biotech company (now part of BMS) based in Seattle.
Previously, from 2009 to 2013, Pat was Executive Vice President and Global Head of Technical Operations at F. Hoffman-La Roche based in Basel, Switzerland. In this role, he was responsible for Roche’s biopharma process research and development, analytical sciences, engineering, quality, technical regulatory, supply chain and all manufacturing plants with approximately 15,000 employees around the world. From 2003 to 2009, Pat was Executive Vice President of Product Operations at Genentech. He assumed his role as Global Head of the combined technical operations of Roche and Genentech upon the acquisition of Genentech by Roche in 2009.
Before Genentech, Pat worked for 11 years at Merck & Company from 1992 to 2003, based in New Jersey, in various leadership positions including vice president of Asia Pacific Operations and vice president of Global Supply Chain Management. Prior to joining Merck in 1992, Pat spent 12 years at General Electric, serving in research, engineering, technology, and manufacturing leadership roles with increasing scope of responsibilities.
Pat holds a Bachelor of Science from the National Chiaotung University in Taiwan, a Master of Science from the University of Cincinnati, and a Ph.D. in engineering from Ohio State University.
Pat is a member of the Board of Directors of three public companies, Amyris, Codexis and PharmaEssentia. In addition, he is on the board of several private companies, including Acepodia, AltruBio, Antheia and Sana Biotechnology.
Pat Yang
Vice Chairman & Co-Founder
Resilience, Inc.
The Biomanufacturing World Summit 2023 gathered top biomanufacturing leaders to share new ideas and collaborate on solutions that inspired a collective vision for change, shaping the future of the industry.
Director of Quality Assurance, Gilead
Director Project Management, Kite Pharma
Executive Director, Head Global Biologics CMC Product Stewardship, AstraZeneca
Executive Director, CMC and QC Biologics, Ultragenyx
General Manager, Advanced Therapies, Thermo Fisher Scientific
VP Process Development, Vir Biotechnology
"*" indicates required fields
By completing and submitting this form, you agree to receive marketing emails from Executive Platforms Inc. You can opt-out at any time by utilizing the unsubscribe link provided at the bottom of each email. All data collected will be handled in accordance with our Privacy Policy and Terms of Use.
"*" indicates required fields
By completing and submitting this form, you agree to receive marketing emails from Executive Platforms Inc. You can opt-out at any time by utilizing the unsubscribe link provided at the bottom of each email. All data collected will be handled in accordance with our Privacy Policy and Terms of Use.
"*" indicates required fields
By completing and submitting this form, you agree to receive marketing emails from Executive Platforms Inc. You can opt-out at any time by utilizing the unsubscribe link provided at the bottom of each email. All data collected will be handled in accordance with our Privacy Policy and Terms of Use.